J&J’s Darzalex nets first self-administered cancer injectable approval
Corroborated by 1 source from 1 publisher
globalhealth4h ago
TL;DR
According to finance.yahoo.com, johnson & Johnson’s (J&J) blockbuster cancer immunotherapy, Darzalex (daratumumab), has secured European approval for self-administration, marking the first time an oncology injectable has achieved this milestone on the continent.